|
Opportunities for Emerging Disease-Modifying Therapies in Multiple Sclerosis
— A Webinar from Decision Resources
You are invited to attend a complimentary webinar from Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues.
This presentation is based on our Treatment Algorithms in Multiple Sclerosis report. This report shows which disease-modifying biologic therapies gain the greatest patient shares in the earliest lines of therapy and the key factors driving therapy choice among physicians. The interferon-beta therapies make up the lion’s share of the multiple sclerosis market, but Teva Pharmaceutical’s Copaxone has been gaining significant market share because of its benign side-effect/safety profile.
Treatment Algorithms in Multiple Sclerosis combines in-depth primary research from 150 surveyed physicians with the most extensive claims-based longitudinal patient-level data from PharMetrics to provide insight on quantitative patient share by lines of therapy for multiple sclerosis.
Presented by Decision Resources Director Madhuri Borde, Ph.D., the webinar will answer the following questions:
- How many newly diagnosed patients with multiple sclerosis are not currently treated with an interferon-beta therapy or Copaxone? What key barriers prevent patients from receiving disease-modifying drug treatment? What opportunity does this present for agents seeking to capture patient share in early-stage disease?
- What factors lead physicians to prescribe one disease-modifying therapy over another? Based on these agents’ positioning in first- and second-line treatment, which attributes have the greatest potential for maximizing patient share?
- According to surveyed physicians, at what point in the treatment algorithm are key emerging therapies—most notably Novartis/Mitsubishi Tanabe’s fingolimod—likely to gain their most use? How will this impact the use of current multiple sclerosis therapies in lines of therapy?
Dr. Borde and Vice President Jason LaBonte, Ph.D., will conduct a live Q & A session after the presentation.
Opportunities for Emerging Disease-Modifying Therapies in Multiple Sclerosis
June 11, 2008 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
To register, click here to reach our WebEx Event Center page, then click "Register" for this event.
For more information, contact Christopher Comfort at ccomfort@dresources.com.
For pricing information on the Treatment Algorithms in Multiple Sclerosis report, please contact Stephen Silvestro at 781-296-2626 or email him at ssilvestro@dresources.com.
|
